TL;DR — Creatine and Depression
Depression is increasingly understood as a disorder involving impaired brain energy metabolism — not merely a neurotransmitter imbalance. The brain uses approximately 20% of the body’s total ATP despite being only 2% of body mass, and the phosphocreatine system is critical for maintaining this energy supply. Kious et al. (2019) reviewed evidence showing that creatine supplementation may enhance the effectiveness of antidepressant medications, particularly SSRIs, with the most consistent findings in women (BM et al., 2019) . Additionally, Toniolo et al. (2017) demonstrated creatine’s potential in bipolar depression. While the evidence is preliminary and creatine should not replace professional mental health treatment, these findings position creatine as a potentially valuable adjunct therapy warranting larger clinical trials.
The Brain Energy Hypothesis of Depression
Traditional models of depression focused primarily on neurotransmitter deficiency — particularly serotonin. While neurotransmitter imbalances play a role, a growing body of evidence points to a more fundamental issue: impaired brain energy metabolism.
The brain is extraordinarily energy-hungry. It runs approximately 86 billion neurons, each forming thousands of synaptic connections that require constant ATP to maintain ionic gradients, release and reuptake neurotransmitters, and support synaptic plasticity. Any disruption to this energy supply can have cascading effects on brain function, including mood regulation.
Multiple lines of evidence support the energy hypothesis:
Neuroimaging findings. Magnetic resonance spectroscopy (MRS) studies have identified reduced phosphocreatine and total creatine levels in the brains of individuals with depression, particularly in the frontal lobe — the region most strongly associated with mood regulation, decision-making, and executive function.
Mitochondrial dysfunction. Depression is associated with impaired mitochondrial function, reducing the brain’s capacity to produce ATP through oxidative phosphorylation. This makes the phosphocreatine buffer system even more critical for maintaining energy supply.
Treatment resistance correlations. Some studies suggest that the degree of brain energy depletion correlates with treatment resistance — patients with more severe energy deficits may respond less well to standard antidepressant therapy.
Wallimann et al. (2011) described the creatine kinase system as having pleiotropic effects beyond energy metabolism, including antioxidant and neuroprotective properties relevant to depression pathophysiology (T et al., 2011) .
The Kious 2019 Review: SSRI Augmentation
Kious et al. (2019) conducted a comprehensive review of creatine for depression treatment, synthesizing the available clinical and preclinical evidence (BM et al., 2019) .
Their key findings included:
Brain creatine alterations in depression. MRS studies consistently show altered creatine and phosphocreatine levels in depressed individuals, providing a biological rationale for supplementation.
SSRI augmentation. The most promising clinical data showed that adding 5g/day of creatine to ongoing SSRI treatment improved depression scores more than SSRI treatment alone, particularly in women with major depressive disorder.
Gender-specific effects. The antidepressant effects of creatine have been most consistently observed in women. This may relate to differences in brain creatine metabolism between sexes, or to hormonal interactions that influence creatine’s neurological effects.
Safety and tolerability. Creatine was well tolerated in depression studies with no significant adverse effects, consistent with the broader safety literature (RB et al., 2017) .
Bipolar Depression: The Toniolo Trial
Toniolo et al. (2017) conducted a randomized, double-blind, placebo-controlled trial of creatine augmentation in bipolar II depression — one of the more rigorous clinical trials in this area (RA et al., 2017) .
The study included 35 participants with bipolar II depression who were randomized to receive either 6g/day of creatine or placebo alongside their existing mood stabilizer treatment. Key results included significantly greater improvement on the Hamilton Depression Rating Scale in the creatine group, earlier onset of antidepressant response, and good tolerability with no increased risk of mania — a critical safety concern in bipolar disorder.
This trial is notable because bipolar depression is notoriously difficult to treat, and few augmentation strategies have shown efficacy in rigorous controlled trials. While the sample size was small, the results are encouraging and support the brain energy hypothesis of mood disorders.
How Creatine May Help Depression
The proposed mechanisms for creatine’s antidepressant effects include:
Restoring brain energy reserves. By increasing brain creatine and phosphocreatine levels, supplementation may help restore the energy buffer that is depleted in depression. This improved energy availability could support better neuronal function and mood regulation.
Supporting neurotransmitter synthesis. Neurotransmitter production is an ATP-dependent process. Improved brain energy availability may support more efficient synthesis of serotonin, dopamine, norepinephrine, and other mood-relevant neurotransmitters.
Enhancing neuroplasticity. Synaptic plasticity — the brain’s ability to form and strengthen connections — requires substantial energy. Creatine supplementation may support the energetic demands of neuroplastic processes that are impaired in depression.
Neuroprotective effects. Roschel et al. (2021) highlighted creatine’s neuroprotective properties, including protection against oxidative stress and excitotoxicity — both of which are implicated in depression-related neuronal damage (H et al., 2021) .
Important Limitations
Creatine is NOT a replacement for professional treatment. Depression is a serious medical condition. If you are experiencing depression, please seek help from a healthcare professional. Creatine should only be considered as a potential complement to established treatments, not a substitute.
The evidence is still preliminary. The clinical trials to date have been small (typically 20-50 participants) and few in number. Larger, multi-center randomized controlled trials are needed before creatine can be recommended as a standard depression treatment.
Most evidence is in women. The strongest clinical findings have been in female participants. Whether creatine provides similar antidepressant benefits in men remains unclear and requires further study.
Standard dosing. The depression studies have used the same 5g/day dose commonly used for athletic performance, suggesting no special dosing protocol is needed.
Malaysian Mental Health Context
Mental health awareness is growing in Malaysia, though stigma remains a significant barrier to seeking treatment. The National Health and Morbidity Survey has documented substantial depression prevalence across the Malaysian population. Several factors make the creatine-depression connection relevant locally:
Growing awareness. Campaigns like MENTARI and increased media coverage are reducing stigma around mental health in Malaysia. Interest in complementary approaches alongside conventional treatment is growing.
Urban stress. High stress from urban lifestyles in Kuala Lumpur, Penang, and Johor Bahru contributes to depression risk. Long commutes, competitive work environments, and cost of living pressures take a toll on mental health.
Complementary approaches. Many Malaysians are interested in natural supplements that can support mental wellness alongside conventional care. Creatine’s strong safety profile makes it a reasonable option to discuss with healthcare providers.
Accessibility. Creatine monohydrate is affordable at RM40-80 per month and widely available through Malaysian retail channels including Shopee, Lazada, and Watsons.
If you or someone you know is struggling with depression in Malaysia, contact Befrienders KL at 03-7956 8145 or the Mental Health Psychosocial Support (MHPSS) line at 03-2935 9935.
Sources & References
This article cites Kious et al. (2019) on creatine for depression, Toniolo et al. (2017) on bipolar depression, Roschel et al. (2021) on creatine and brain health, Wallimann et al. (2011) on the creatine kinase system, and the ISSN position stand by Kreider et al. (2017). Full citations with DOI links are available in our Research Library.